#U.S. Next Generation Diabetes Therapy and Drug Delivery Market opportunity | Explore Tumblr Posts and Blogs

meditech-insights · 2 years

Text

Interventional Cardiology Devices Market valued at US$ 6.7 billion in 2021, is expected to grow at a CAGR of 2 to 3% by 2026

Interventional cardiology is a branch of cardiology that utilizes nonsurgical, catheter-based treatments for structural heart diseases. It makes use of devices such as catheters & sheaths, guidewires, balloons, stents, vascular closure devices, atherectomy devices, intravascular ultrasound (IVUS), and other devices to repair narrowed arteries, damaged or weakened blood vessels, heart valve disorders, and congenital heart diseases.

The Global Interventional Cardiology Devices Market valued at US$ 6.7 billion in 2021 is set to witness a growth rate of ~2 to 3% in the next 5 years. The rising geriatric population & corresponding rise in the prevalence of coronary artery diseases, rising occurrence of diabetes & concomitant increased risk of coronary heart disease, technical developments in interventional cardiology devices, and favorable reimbursements for interventional cardiology procedures are some of the key factors driving the global interventional cardiology devices market.

APAC to Witness Highest Growth in the Next Five Years

An increasing occurrence of cardiovascular diseases & hypertension, a higher degree of unmet clinical needs, and rising affluence are creating ample opportunities for the interventional cardiology devices market in the APAC region. The development of the interventional cardiology devices market in the APAC is likely to be driven by China and India. Considering the lucrative prospects of the interventional cardiology devices market in the APAC region, prominent companies have expanded their footprint in the region.

For instance,

In March 2022, Boston Scientific expanded its footprint in India with its second R&D Center. The new R&D Center addresses the needs of the patients in India, APAC, and around the world. It also provides expertise to all of the company’s diverse therapy areas, namely interventional cardiology, peripheral interventions, cardiac rhythm management, endoscopy, neuromodulation, urology, and pelvic health

Abbott also intends to expand coverage and resources in training programs related to cardiovascular treatment in China. Abbott owns two training centers in China. The Abbott Medical Advanced Technology Center in Beijing provides doctors with first-class cardiological learning experiences and practice opportunities. The Crossroads-Abbott Academic Center in Shanghai provides interventional treatment training for physicians from different regions in China, making medical treatment and standardized treatment and care more accessible to patients in remote areas

“China is one of the most prominent markets for cardiovascular diseases. The demand from patients to be treated as well as doctors to get trained is humongous. This is why interventional cardiology device manufacturers are investing in China."- Director, Leading Stent Manufacturer, United States

Explore Premium Report on Interventional Cardiology Devices Market @ https://meditechinsights.com/interventional-cardiology-devices-market/

Technological Advancements Drive the Market

The interventional cardiology devices market is a technology-driven market and is noticeable by product enhancements/innovations.

For instance,

In May, 2022, Medtronic received U.S. FDA approval for the Onyx Frontier™ drug-eluting stent (DES). The Onyx Frontier DES is used for the treatment of patients with coronary artery disease (CAD). It offers an innovative delivery system and builds upon the acute performance and clinical data from the Resolute Onyx™ drug-eluting stent

In April 2022, Translumina launched VIVO ISAR, its latest generation dual drug polymer-free coated stent (DDCS), in various international markets including Europe

Organic and Inorganic Growth Strategies Adopted by Players to Establish Their Foothold

The interventional cardiology devices market is characterised by the presence of both established and new players. Players operating in the market adopt both organic and inorganic growth strategies such as acquisitions, and new product launches to gain market share.

For instance,

In April 2022, Transit Scientific announced the FDA clearance of its XO Cross® Support Catheter Platform to include coronary use. The platform is indicated to guide and support a guidewire during access of the peripheral or coronary vasculature, allow for wire exchanges, and provide a conduit for delivery of saline solutions or diagnostic contrast agents

In April 2022, Boston Scientific announced the close of its acquisition of Baylis Medical Company Inc., a company that offers advanced transseptal access solutions as well as guidewires, sheaths and dilators used to support catheter-based left-heart procedures. The acquisition allows Boston Scientific to integrate the Baylis platforms with its existing electrophysiology and structural heart offerings, further strengthening its position in the cardiology market

The interventional cardiology devices market is anticipated to continue to grow in the coming years due to rising cardiovascular cases, growth opportunities in the APAC region, technical developments in interventional cardiology devices, and favorable reimbursement in key markets.

Competitive Landscape Analysis of Interventional Cardiology Devices Market

The interventional cardiology devices market is marked by the presence of players such as Medtronic, Boston Scientific, Abbott, Medinol, Biotronik, SMT, Terumo, Lepu Medical, Microport, among others.

For More Comprehensive Insights, Contact Us @ https://meditechinsights.com/contact-us/

About Medi-Tech Insights

Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services.

Contact:

Ruta Halde

Associate, Medi-Tech Insights

+32 498 86 80 79

[email protected]

#Healthcare #Interventional-Cardiology-Devices-Market

0 notes

kdmarketresearch · 5 years

Text

U.S. Next Generation Diabetes Therapy and Drug Delivery Market – Top players Abbott Laboratories,Echo Therapeutics, Inc.,F. Hoffmann-La Roche Ltd, GlySens Incorporated, Medtronic Plc, Sanofi, Novo Nordisk, MannKind Corporation, Dexcom, Inc, Senseonics Holding, Inc.

KD Market research has presented a detailed report on “U.S. Next Generation Diabetes Therapy and Drug Delivery Market ” which includes the major application, advantages, and key market trends that are fostering the growth of the market during the forecasted span of 6 years. The research takes a step forward and analyzes the key competitors and global regions that are holding the market share of U.S. Next Generation Diabetes Therapy and Drug Delivery Market in terms of revenue.

Request for sample@ https://www.kdmarketresearch.com/sample/3441

The U.S. next generation diabetes therapy and drug delivery market was valued at $446 million in 2015, and is estimated to reach $6,510 million by 2023, registering a CAGR of 33.0% from 2017 to 2023. Next generation diabetes therapy and drug delivery devices are used to accurately check the blood glucose levels and deliver insulin into the body. Next generation diabetes drug delivery systems such as oral and inhalable insulin help to introduce insulin into the patient?s body without causing pain and also reduces the risk of skin irritation due to frequent use of needles.

The U.S. next generation diabetes therapy and drug delivery market is segmented based on product type, demographic, end user, and region. The product type segment includes inhalable insulin, oral insulin, insulin patch, continuous glucose monitoring systems (CGMS), and artificial pancreas. Based on demographic, the market is bifurcated into adult population (>14years) and child population (=14years). Based on indication, the market is divided into diabetes I and II. Based on end user, the market is categorized into diagnostics/clinic, ICU, and home healthcare.

Rise in the number of diabetic cases and the benefits of using these advanced devices over conventional products boost the market growth. The well-established healthcare infrastructure and high R&D activities for the advancement in diabetes therapeutic technology are expected to provide opportunities for market growth. However, less variability in products and cost restraints among low and middle-income population are expected to hinder the market growth. Development of affordable products with fewer side effects and presence of undiagnosed diabetic patients in the U.S. are projected to help to open new doors for the growth of the next generation diabetes therapy and drug delivery market.

KEY MARKET BENEFITS This report offers a detailed quantitative analysis of the current market trends from 2014 to 2023 to identify the prevailing opportunities. The market estimations provided are based on comprehensive analysis of the key developments in the industry. The U.S. next generation diabetes therapy and drug delivery market is comprehensively analyzed with respect to product type, demographics, indications, and end user. The development strategies adopted by key manufacturers are enlisted to understand the competitive scenario of the market.

KEY MARKET SEGMENTS

By Product Type Inhalable Insulin Oral Insulin Insulin Patch CGM System Artificial Pancreas

By Demographic Adult Population (>14 years) Child Population (=14 years)

By End User Diagnostics/Clinic ICU Home Healthcare

KEY PLAYERS PROFILED Abbott Laboratories Echo Therapeutics, Inc. F. Hoffmann-La Roche Ltd. GlySens Incorporated Medtronic Plc Sanofi Novo Nordisk MannKind Corporation Dexcom, Inc. Senseonics Holding, Inc.

The other players of the catheters market include (companies not profiled in the report): Synertech Zosano Pharma Corp. Relmada Therapeutics, Inc. Eli Lilly and Company Enteris BioPharma Transdermal Specialties Inc

browse full report with toc@ https://www.kdmarketresearch.com/report/3441/us-next-generation-diabetes-therapy-and-drug-delivery-market-amr

Table of content

CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION 1.2. KEY BENEFITS 1.3. KEY MARKET SEGMENTS 1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research 1.4.2. Primary research 1.4.3. Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. KEY BENEFITS

3.1.1. Top investment pockets 3.1.2. Top winning strategies

3.2. PATENT ANALYSIS

3.2.1. Patent analysis by year 3.2.2. Patent analysis by product

3.3. GOVERNMENT REGULATIONS

3.3.1. U.S. FDA

3.4. REIMBURSEMENT POLICIES 3.5. INNOVATIONS IN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET

3.5.1. Smart contact lenses for glucose monitoring 3.5.2. iLet bihormonal bionic pancreas 3.5.3. Glucose nanosensors 3.5.4. Beta cell replacement therapy 3.5.5. Glucose-responsive insulin-producing cells

3.6. MARKET DYNAMICS

3.6.1. Drivers

3.6.1.1. Rise in incidence of diabetes 3.6.1.2. Rise in healthcare expenditure & disposable income 3.6.1.3. Benefits of using next generation diabetes products over conventional products

3.6.2. Restraints

3.6.2.1. Cost restrains 3.6.2.2. Lack of awareness 3.6.2.3. Less variability in products

3.6.3. Opportunities

3.6.3.1. Developing products with fewer side effects at affordable costs 3.6.3.2. High undiagnosed diabetic patient population

CHAPTER 4 NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY PRODUCT

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. INHALABLE INSULIN

4.2.1. Key market trends 4.2.2. Key growth factors and opportunities 4.2.3. Market size and forecast

4.3. ORAL INSULIN

4.3.1. Key market trends 4.3.2. Key growth factors and opportunities 4.3.3. Market size and forecast

4.4. INSULIN PATCHES

4.4.1. Key market trends 4.4.2. Key growth factors and opportunities 4.4.3. Market size and forecast

4.5. CGMS

4.5.1. Key market trends 4.5.2. Key growth factors and opportunities 4.5.3. Market size and forecast

4.6. ARTIFICIAL PANCREAS

4.6.1. Key market trends 4.6.2. Key growth factors and opportunities 4.6.3. Market size and forecast

CHAPTER 5 NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY DEMOGRAPHICS

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. ADULT POPULATION (>14YEARS)

5.2.1. Market size and forecast

5.3. CHILD POPULATION (14YEARS)

5.3.1. Market size and forecast

CHAPTER 6 NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY INDICATION

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. TYPE I DIABETES

6.2.1. Market size and forecast

6.3. TYPE II DIABETES

6.3.1. Market size and forecast

CHAPTER 7 NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY END USER

7.1. OVERVIEW

7.1.1. Market size and forecast

7.2. DIAGNOSTICS/CLINICS

7.2.1. Market size and forecast

7.3. INTENSIVE CARE UNITS (ICU)

7.3.1. Market size and forecast

7.4. HOME HEALTHCARE

7.4.1. Market size and forecast

CHAPTER 8 COMPANY PROFILES

8.1. ABBOTT LABORATORIES

8.1.1. Company overview 8.1.2. Company snapshot 8.1.3. Operating business segments 8.1.4. Product portfolio 8.1.5. Business performance 8.1.6. Key strategic moves and developments

8.2. DEXCOM, INC.

8.2.1. Company overview 8.2.2. Company snapshot 8.2.3. Product portfolio 8.2.4. Business performance 8.2.5. Key strategic moves and developments

8.3. ECHO THERAPEUTICS, INC.

8.3.1. Company overview 8.3.2. Company snapshot 8.3.3. Operating business segments 8.3.4. Product portfolio

8.4. F. HOFFMANN-LA ROCHE LTD.

8.4.1. Company overview 8.4.2. Company snapshot 8.4.3. Operating business segments 8.4.4. Product portfolio 8.4.5. Business performance 8.4.6. Key strategic moves and developments

8.5. GLYSENS INCORPORATED

8.5.1. Company overview 8.5.2. Company snapshot 8.5.3. Product portfolio 8.5.4. Key strategic moves and developments

8.6. MANNKIND CORPORATION

8.6.1. Company overview 8.6.2. Company snapshot 8.6.3. Operating business segments 8.6.4. Product portfolio 8.6.5. Business performance

8.7. MEDTRONIC PLC.

8.7.1. Company overview 8.7.2. Company snapshot 8.7.3. Operating business segments 8.7.4. Product portfolio 8.7.5. Business performance 8.7.6. Key strategic moves and developments

8.8. NOVO NORDISK A/S

8.8.1. Company overview 8.8.2. Company snapshot 8.8.3. Operating business segments 8.8.4. Product portfolio 8.8.5. Business performance

8.9. SANOFI

8.9.1. Company overview 8.9.2. Company snapshot 8.9.3. Operating business segments 8.9.4. Product portfolio 8.9.5. Business performance 8.9.6. Key strategic moves and developments

8.10. SENSEONICS HOLDINGS, INC.

8.10.1. Company overview 8.10.2. Company snapshot 8.10.3. Operating business segments 8.10.4. Product portfolio 8.10.5. Business performance 8.10.6. Key strategic moves and developments

Check for discount @ https://www.kdmarketresearch.com/discount/3441

About Us:

KD Market Research is one of the best market research organization that provides B2B research on the growth opportunities of the industry which is the prime factor of the overall revenue of the organization. We identify the pain points which our client is facing around revenue methods and provide them with a comprehensive database which helps them to make intelligent decisions that could ensure growth to the organization.

Our Services include market intelligence, competitive intelligence, and customized research. These research reports help the organizations to make quick and powerful decisions that make out highest growth in revenue.

150 State Street, Albany,

New York, USA 12207

Email id [email protected]

#U.S. Next Generation Diabetes Therapy and Drug Delivery Market size #U.S. Next Generation Diabetes Therapy and Drug Delivery Market trends #U.S. Next Generation Diabetes Therapy and Drug Delivery Market opportunity #U.S. Next Generation Diabetes Therapy and Drug Delivery Market forecast

0 notes

market-research-future · 4 years

Text

Africa Medical Devices Market Opportunities, Dynamics, Global Industry Analysis

Africa Medical Devices Market Information, by Product type (Monitoring Devices, Diagnostic devices, Diagnostic Molecular Devices, Drug delivery devices, Surgical Devices, Bio implants and Stimulation Devices, Automation and Robotics and Others), by Therapeutic Application (General Surgery, Diagnostic Imaging, Respiratory, Orthopedics, Cardiovascular, Dental, Neurology, Ophthalmology, Ear-Nose-Throat (ENT), Nephrology and Urology, and Others) and by End User (Hospitals, Ambulatory and Home) - Forecast to 2023

Africa Medical Devices Market Regional Analysis

The Africa Medical Devices Market is growing rapidly in Africa region owing to upgrade of hospitals, introduction of health insurance policy, and rapidly growing middle-income group. Government is focussing more to improve the life of their citizen, thus they are more focusing on the establishment of best hospitals in the region. This region is more focusing towards new technology and advance treatment option; thus the local players are focusing more into mergers and acquisition and research and development programs for the development of Medical devices. These are the factors which are fuelling the growth of the market of medical devices with the significant rates in this region.

Company such as Koninklijke Philips Electronics NV, Siemens AG, Medtronic Public Limited, and GE Healthcare have already a huge presence in Africa region owing to the collaboration they made and strategy of expanding their sales network within the region. The markets of Africa region are very different and still shaping and growing. Although most of the products are imported within the region, but the government is focusing to develop this equipment in their premises to minimize the cost of medical devices.

Most of the major players such as Johnson & Johnson (U.S.), Mindray Medical International Limited (China), Koninklijke Philips Electronics NV (Netherlands), Siemens AG (Germany), Toshiba Medical Systems Corporation (Japan), GE Healthcare (U.K), Medtronic Public Limited (U.S.), Baxter International Inc. (U.S.), Cardinal Health, Inc. (U.S.), Saudi Pharmaceutical Industries & Medical Appliances Corporation (Africa), and Al Faisaliah Medical Systems (Africa) are looking forward in this region to minimize the gap of between demand and supply of advance medical devices and maximize the profit sharing ration.

Competitive Analysis

Companies are continuously engaged in merger and acquisition activities for the development of the best medicine to cure affected population. Although the government stick rule hindering the growth of the market. In May 2017, Baxter International Inc. and Mayo Clinic announced a collaboration for the research and development to advance a spectrum of therapeutic areas to minimize the unmet patient needs. These collaborations help market players to lead the Africa Medical Devices Market. Most of the players from this region involve in the collaboration with global players to get advanced technology, which help them to maximize the market share in this region. Although limited infrastructure, lack of physicians, and restricted funding and reimbursement policy are the restraints factor for the growth of the market.

Johnson & Johnson (U.S.), Mindray Medical International Limited (China), Koninklijke Philips Electronics NV (Netherlands), Siemens AG (Germany), Toshiba Medical Systems Corporation (Japan), GE Healthcare (U.K), Medtronic Public Limited (U.S.), Baxter International Inc. (U.S.), Cardinal Health, Inc. (U.S.), Saudi Pharmaceutical Industries & Medical Appliances Corporation (Africa), and Al Faisaliah Medical Systems (Africa) are some of the leading players at the cutting edge of the competition in the Africa Medical Devices Market

Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/1813

Overview

Any instrument, apparatus, implement, implant, reagent that is used for human beings, for diagnosis, detecting, restoring, correcting, prevention, monitoring, treatment of disease and injury are known as medical devices. Technological advancement plays an important role in the growth of any sector. Most of the market players play an important role to develop the market of medical devices in Africa. For instance, in 2015, Elekta and ministry of health working together in almost a dozen African nations to develop their radiation therapy infrastructures for curing lives.

It is expected that Africa’s macroeconomic climate over the next decade will expand the health care gap, as higher incomes will create new demand for the medical devices market. Additionally, government also introduces some laws for maintaining the quality of medical devices. According to a report published by the International Diabetes Federation, in 2017, more than 16 million people are suffering with diabetes in the AFR Region. Increasing number of incidences are the main factors which drag the attention of players towards this region.

The Africa Medical Devices Market is growing with a steady pace; mainly due to the rapidly growing middle-income group, increasing healthcare expenditure, increasing number of medical tourists, proliferation of hospitals, government programs and support, and increasing incidence of lifestyle diseases.

Moreover, rising economic growth also drive the market in this region. According to the World Bank Group, in 2016, GDP of the Middle East & North Africa experienced the growth in GDP by 4.89%.

Browse Detailed Table of Content at: https://www.marketresearchfuture.com/reports/africa-medical-devices-market-2845

Brows More Healthcare Related Research Reports:

Infrared Spectroscopy Devices Market Size, Trends | Growth Analysis, 2023

Asia-Pacific Glaucoma Treatment Market Trends, Size Analysis | Applications, 2023

Diabetes Market Research Report Forecast To 2023 | MRFR

NOTE: Our team of researchers are studying Covid19 and its impact on various industry verticals and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact:

Akash Anand

Market Research Future

+1 646 845 9312

Email: [email protected]

0 notes

technicallyyoungkitten · 4 years

Text

Wearable Patch Market- Size, Share, Outlook, and Opportunity Analysis, 2020- 2027

Wearable patches are known as smart patches or electronic skin. These are thin, small, and flexible in nature, and are used for disease monitoring, drug delivery, and diagnosis. Wearable patches help to maintain health and wellbeing in elderly patients suffering from chronic conditions such as diabetes and others. Presently, the market of wearable technologies is growing, owing to increasing research and development activities for development of wearable patch carried out by key players operating in the market. Wearable patches can be worn or stuck to the skin, or patch’s such as scopolamine patches and transdermal patch are directly attached to the affected body part for disease monitoring. For instance, a nicotine path is a transdermal patch, which releases nicotine into the body, and is used in nicotine replacement therapy (NRT).

Request a sample copy of this report:- https://www.coherentmarketinsights.com/insight/request-sample/2891

The global wearable patch market size is expected to be valued at US$ 318.1 million in 2019, and is expected to exhibit a CAGR of 22.9% over the forecast period (2019-2027).

Increasing prevalence of chronic diseases such as diabetes and atrial fibrillation is resulting in high number of stroke incidents, which is expected to drive growth of the wearable patch market over the forecast period. For instance, according to the International Diabetes Federation report published in November 2019, around 463 million adults between the age group of 20 to 79 years were diagnosed with diabetes across the globe, and it is expected that the total diabetes population will reach around 700 million by 2045 globally.

Moreover, according to the American Heart Association, January 2019, stroke was a leading cause of death in the U.S. with around 2.7 million people in the country living with atrial fibrillation and around 800,000 people encounter stroke, annually, due to blockage in the blood vessel, which supplies blood to the brain. Therefore, increasing prevalence of atrial fibrillation is expected to boost growth of the wearable patch market.

Wearable patches are used for monitoring and diagnosis of chronic diseases. Increasing prevalence of diseases such as atrial fibrillation has led to increase in demand for wearable patches for early diagnosis. This rising demand has led by major players in the market to launch new and technologically advanced wearable patch. For instance, in July 2018, LifeSignals, a solution provider for health and wellbeing, received the U.S. Food and Drugs Administration (FDA) approval for wireless LP1100 Life Signal Patch, a next generation wearable healthcare monitoring device. LP1100 Life Signal Patch is a clinical-grade, two-lead ECG, and heart rate monitoring patch, which has three-day monitoring capacity.

Furthermore, in November 2018, L’Oreal and La Roche-Posay launched ‘My Skin Track UV’, a wearable skin and sun safety sensor to help women and men to track their personalized exposure to UV, pollution, pollen, and humidity.

However, high cost of sensor monitoring patch is expected to hinder growth market growth in emerging economies such as India, Brazil and China. The average price of ECG sensor patch is around US$ 300 to US$ 4,500. Market players, who can address the cost issue and can offer high quality products in emerging economies are expected to enhance their market share in the particular region.

Major players operating in the global wearable patch market include Medtronic Plc, Hill-Rom Holdings, Inc. (Welch Allyn), iRhythm Technologies, Inc., AliveCor, Inc., Vivalnk, Inc., Cardiac Insight Inc., VitalConnect, LifeSignals, Inc., L’oreal Group, Dexcom, Inc., GENTAG, Inc., Abbott Laboratories, and Koninklijke Philips N.V.

Get the main link:- https://www.coherentmarketinsights.com/market-insight/wearable-patch-market-2891

Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [email protected] Visit our news Website: http://www.coherentchronicle.com/

0 notes

niranjan20 · 4 years

Link

U.S. next generation diabetes therapy and drug delivery market is growing at a CAGR of 33.0%, projected to reach $6,510 million by 2023.

#U.S. NextGeneration Diabetes Therapy and Drug Delivery Market

0 notes

pharmanewstrands-blog · 5 years

Text

Insulin Delivery Devices Market Expert analysis: Industry, governing, innovation and technological trends

Insulin Delivery Devices Market - Insights

Insulin is vital for people suffering from type 1 diabetes and type 2 diabetes. In the past, patients with diabetes had to inject insulin using large glass syringes and reusable needles, both of which needed sterilization by boiling after each use. Improvements and innovations has led to development of insulin delivery devices such as pens and insulin pumps. Furthermore, insulin analogs have become available that enable both continuous subcutaneous insulin infusion(CSII) using an insulin pump and insulin therapy using multiple daily injections (MDI) to more closely match physiologic insulin patterns.

Type or dosage of insulin can be changed, to meet the individual needs of the patient. Insulin can be packaged in vials (bottles), cartridges or prefilled pens. The cartridges are used with pen injectors whereas the vials are used with syringes.

The global insulin delivery devices market was valued at US$ 11,326.9 million in 2017 and is expected to witness a CAGR of 11.3% over the forecast period (2017–2025).

Request A Sample Copy: http://bit.ly/2Yg0Vn4

Increasing prevalence of diabetes is expected to drive growth of the insulin delivery devices market over the forecast period

Increasing prevalence and incidence of diabetes is a major factor driving the insulin delivery devices market growth. According to the Centers for Disease Control and Prevention (CDC), 2014, about 29.1 million people in the U.S. have diabetes with a healthcare burden of around US$ 245 Bn and with an estimated 4.6–9.2% of pregnant women affected by gestational diabetes. Moreover, the Australian government launched National Diabetes Strategy (2016–20), for an action to prevent diabetes and support the people living with diabetes. Thus, rise in government initiatives to support diabetic patients is expected to favor growth of the insulin delivery devices market.

Development of systems and devices for improved drug delivery is expected to be factor for growth of the market. When compared with vial and syringe regimens, insulin pens offer a greater clinical efficacy, improved quality of life, and increased dosing accuracy, particularly at low doses. Thus, introduction of insulin pen devices has aided patients with diabetes mellitus in easier and more convenient treatment regimens. For instance, in January 2014, Novo Nordisk launched the NovoPen Insulin Delivery Devices MarketEcho in the U.S. market. This is the first and only pen device available in the U.S. with half-unit dosing and a memory function that can record the dose and time passed since the last injection.

Increasing adoption of advanced devices for insulin delivery is driving growth of the market

Increasing awareness among population regarding insulin delivery devices coupled with high demand for insulin administration for diabetes control are the factors driving growth of the market. Among region, North America, accounted for largest market share in insulin delivery devices, followed by Europe, owing to high prevalence of lifestyle associated diseases, implementation of awareness programs regarding diabetes, and high adoption of advanced medical devices. For instance, in 2010, according to Journal of Diabetes Science and Technology, majorly insulin pumps were used on the American side of the Atlantic than on the European side, which is projected to propel demand for insulin pumps over the forecast period.

Furthermore, in 2016, the UAE Ministry of Health and Prevention in partnership with the Emirates Diabetes Society and Ministry with AstraZeneca Gulf, launched Circle of Care, an education and support Programme, which intends to improve the well-being of people in the UAE suffering from or at risk of developing type 2 diabetes, in turn fueling growth of the market over the forecast period.

Key players in the market are focusing on developing next generation devices to remain competitive, while seeking ways to enhance their design capabilities. For instance, in October 2017, Eli Lilly and Company announced its plans to invest US$ 72 million in an insulin manufacturing project at one of its Indianapolis facilities.

The investment will be used to replace an existing insulin vial filling line and allow Lilly to meet growing demand for its insulins - including Humalog (insulin lispro) and Humulin (human insulin) - while upgrading to state-of-the-art technology and preparing for its insulin pipeline.

Click To Read More On: Insulin Delivery Devices Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Mr.Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email:[email protected]

#insulin delivery devices marketinsulin delivery devices market trendsinsulin delivery devices market growth

0 notes

ellinahussey · 4 years

Text

Human Microbiome Market Size & Share, Application Analysis, Regional Outlook, Growth Trends, Key Players and Competitive Strategies - Forecast to 2025

Human Microbiome Market is valued at USD 210.3 Million in 2018 and expected to reach USD 744.6 Million by 2025 with the CAGR of 19.8% over the forecast period.

Human Microbiome Market report is segmented on the basis of product type, diseases, application and region & country level. Based on product type, global human microbiome market is classified as probiotics, prebiotics, symbiotics, and others. Based upon diseases, global human microbiome market is classified into obesity, diabetes, autoimmune disorder, cancer, gastrointestinal disorders, central nervous system disorders, and others. Based upon application, global human microbiome market is classified as therapeutics and diagnostics.

Get Sample of This Report@ https://brandessenceresearch.com/requestSample/PostId/483

Market Analysis of Human Microbiome–

The human microbiome is the aggregate of all microbiota that resides on or within any of a number of human tissues and bio fluids, including the skin, mammary glands, placenta, seminal fluid, uterus, ovarian follicles, lung, saliva, oral mucosa, conjunctiva, biliary, and gastrointestinal tracts. It includes; bacteria, archaea, fungi, protists and viruses. As per recent estimates, a human body harbors microorganism having a ratio of 3:1 compared to the number of human cells present. The relationship of most microbes with the human bodies ranges from being commensal and mutualistic to neutral and harmful. Human microbiome-based therapies are available in the form of foods, prebiotics, diagnostic devices, probiotics, medical foods, drugs, and supplements. Technological advancements in metagenomics and next-generation sequencing have made microbiome-based testing easier and cheaper, and have led to the rapid analysis of the genomic content of microorganisms from human sample. This has boosted the development process for microbiome-based diagnostics.

Key Players-

Global human microbiome market report covers prominent players like Avidbiotics Inc., Avidbiotics Corp., 4D Pharma, Series Therapeutics, Second Genome, Enterome, MicroBiome Therapeutics, LLC, Rebiotix Inc., Yakult Honsha Co., Ltd., Osel Inc., Vedanta Biosciences, Inc., Metabiomics Corporate, Synthetic Biologics, Inc., DuPont, BiomX Ltd., and others.

The regions covered in this human microbiome market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, market of Human Microbiome is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.

Market Segmentation: –

By Product Type:

Probiotics, Prebiotics, Symbiotics, Other Products

By Application:

Therapeutics, Diagnostics

Market Dynamics–

The increasing incidences of lifestyle diseases are expected to drive the growth of the global human microbiome market. According to the World Health Organization, in 2016, 13% of world population (adults) was obese. As per New Era of Treatment of Obesity and Metabolic Disorders, published in 2016, microbes residing in the human gastrointestinal tract act as an endocrine organ, whose composition and functionality contribute to the development of obesity. However, stringent government regulations related to the approval of human microbiome-based therapies are creating a major weakness to the growth of the market. Moreover, growing investments by governments in the development of human microbiome-based therapies are creating abundant growth opportunities for the global market for human microbiome.

North America is Expected to Dominate the Global Market–

North America is expected to dominate the global human microbiome market and held major market share due to the growing funding and research and development activities by companies and research institutes in this region. The presence of a large number of players who are adopting various initiatives such as investment in research and development for the development of the new therapeutic area for microbiome to prevent health issues such as irritable bowel syndrome, immune diseases, etc. is further contributing to the market in this region.

Full Research Report @ https://brandessenceresearch.com/healthcare/human-microbiome-market-development

About us: Brandessence Market Research and Consulting Pvt. Ltd.

Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals, and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations, and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.

Website: https://brandessenceresearch.com/

Article: https://businessstatsnews.com

Blog: http://www.dailyindustrywatch.com

Blog: https://marketsize.biz

Blog: https://technologyindustrynews.com

Blog: https://marketstatsreport.com

Blog: https://tcbiznews.com/

#Human Microbiome Market #Human Microbiome Market Size #Human Microbiome Market Share #human microbiome market growth

0 notes

maxihealth · 5 years

Text

Prescription Drug Costs In America Through the Patient Lens, via IQVIA, GoodRx and a New $2 Million Therapy

Americans consumed 17.6 prescriptions per person in 2018, two in three of which treated chronic conditions. Welcome to Medicine Use and Spending in the U.S. , the annual review of prescription drug supply, demand and Rx pricing dynamics from the IQVIA Institute for Human Data Science.

In a call with analysts this week in which I participated, Murray Aitken discussed the report which looks back at 2018 and forward to 2023 with scenarios about what the U.S. prescription drug market might look like five years from now.

The report is organized into four sections: medical use trends; costs and spending on meds and growth dynamics underlying the top line numbers; patient out-of-pocket costs; and that five-year forecast to 2023. It’s a richly detailed report with a mine of data; in this Health Populi post, I’ll focus through the patient lens of Rx spending, medication adherence out-of-pocket costs, prescription drug abandonment, and the role of “place” in personal drug pricing.

The big picture on medical use trends is shown in the first bar chart, illustrating that: more Americans took more meds than ever in 2018. These prescriptions are increasingly filled as 90-day supplies of drugs via mail order or retail pharmacy channels. Two-thirds of Rx’s were dispensed to treat chronic conditions, notably hypertension, mental health, lipid management, diabetes, and anti-coagulants. Medicines treating hypertension experienced the largest absolute growth in number of scripts, up 48 million in 2018 over 2017; this increase was driven by an aging population and expanded guidelines in place for the treatment of high blood pressure.

Increases in prescriptions for chronic conditions were also due to growing attention to prescription drug adherence by patients. This is a good news aspect of the IQVIA report, as adherence can be a win-win-win for patients, prescribers and manufacturers alike. In 2018, we saw more incentives to inspire adherence to prescription drug regimens, particularly in Medicare Part D along with increasing focus by pharmacists and providers.

As the second chart details, adherence among patients enrolled in Medicare Part D prescription drug coverage (the green bar) had the highest levels across the three payment sources studied and in all U.S. regions.

Adherence is not equal across every state in America, IQVIA Institute learned: for major chronic conditions of hypertension, cholesterol and diabetes, adherence was a low of around 50% among Medicaid enrollees in Arkansas, Iowa and New York; and as high approaching 90% in Minnesota for Medicare Part D enrollees in that state. Vermont and Minnesota had generally higher adherence across all three payor types, versus relatively low adherence among residents in DC and Mississippi.

Another interesting aspect of medicine usage in 2018 was the adoption new flu and shingles vaccines, which outpaced other new drug starts last year. Nearly 9 in 10 new therapy starts in 2018 were in vaccines, with the rest in traditional medicines. In 2018, forty percent of new therapy starts were for Shingrix, the shingles vaccine. In 2017, nearly 60% of new therapy starts were for the Flucelvax Quadrivalent flu vaccine.

Generics have gone beyond mainstream: they’re universally used by patients who filled a prescription in 2018. When generics were available, they were dispensed 97% of the time in 2018, the third line chart demonstrates. Generic drugs comprised 90% of all dispensed prescriptions in 2018, and in many therapeutic areas generics are dispensed at near 100% of the time.

The generics story feeds into the next section of the IQVIA Institute report which quantifies medicine spending. In 2018, the total market for prescription drug spending in the U.S. was $344 billion, a 4.5% increase over 2017 net of rebates, discounts, and price concessions. This growth rate was a relative historic low level.

On a per capita basis, those $344 bn calculated to $1,044, about $10 up from 2017 and $44 up over a decade ago.

Based on that $44 increase per person in 10 years, Aitken said that relatively low level of increase in per capita spending for medicines was “lower than headlines often suggest.”

Specialty medicines are becoming a more important part of total medicines spending. IQVIA defines specialty medicines as those that treat chronic, complex or rare diseases and share several key characteristics related to their distribution, care delivery, and/or cost of the therapies: specifically, with a list price over $6,000 per year.

Specialty meds are reaching nearly one-half of medicine spending as patents expire for branded drugs and much lower-cost generics are so universally dispensed. The growth in spending is largely driven by oncology, autoimmune disease therapies, treatment for diabetes, and Hep C meds. These four classes generated over 75% of total medicine spending growth in 2018.

The growing proportion and cost of specialty drugs segues us to the next part of the IQVIA report plotline: patient out-of-pocket (OOP) costs. This takes us from the pharma manufacturer’s perspective to the patient’s role in the Rx ecosystem.

Total patient OOP costs in 2018 reached $61 billion, up $2 bn from 2017, and $5 bn from 2014. Just under 9% of patients across all three health plan types had over $500 in OOP costs in 2018. For people enrolled in Medicare Part D, 20% faced over $500 in OOP costs.

When it comes to OOP costs and patient cost exposure, there’s a direct relationship between level of cost and level of prescription abandonment. That’s the scenario when an Rx was written and sent to the pharmacy but ultimately, the patient does not pick up the medicine — thus, “abandoning” it.

Patients abandon over 20% of new prescriptions when their OOP costs rise above $50. A cost of $125 or more yields abandonment of at least 50%. The bar chart here illustrates abandonment rates for patients in commercial and Medicare plans.

Looking to the future toward 2023, IQVIA identified a roster of policies that relate to the American Patients First Blueprint that President Trump and Secretary of Health and Human Services Alex Azar unveiled in 2018. IQVIA identified several at higher probabilities of adoption, including eliminating the payer rebate safe harbor, establishing international benchmark reimbursement, capping patient costs in the catastrophic phase, reducing protected classes limitations, and eliminating cost-sharing on generics, among other provisions.

Heath Populi’s Hot Points: To complement the IQVIA Institute report, I wanted to provide some topline data from the first GoodRx Quarterly Report, published in late April 2019 based on data from the first quarter of 2019 (January 1-March 31, 2019).

Drugs continue to get more expensive, GoodRx notes, with the average list price set by manufacturers growing 2.9% over all generics and brands. GoodRx found a “huge spike” in Rx price increases in the first week of January 2019.

The 20 most expensive medications in the U.S. cost more than $25,000 for a monthly supply.

And, place matters when it comes to drug pricing, shown in the map and top-10 chart here from the GoodRx report. Living in New York City and San Francisco will price you at least 14% above the national average of drug costs, the two towns with double-digit margins above the national average of Rx’s.

If you live in greater Atlanta, you’re in luck: prescription medicines are priced about 20% lower than national average there, similarly in Dallas, Houston and Denver.

It’s important to note that place does indeed matter to the individual patient, as I point out in my book, HealthConsuming: From Health Consumer to Health Citizen. “Place matters” due to our ZIP code so profoundly influencing our health beyond our genetic code, for healthy food access, transportation, broadband connectivity, clean air and water, job opportunities and education….and here GoodRx reveals, drug pricing.

I had the opportunity to brainstorm for a few minutes with IQVIA’s Murray Aitken about the study, and my question about those “headlines” he mentioned in his remarks. In my book, I highlight EpiPen and insulin prices as current examples of patient-consumer uproar, taking the patient-facing costs of these two life-sustaining therapies as quite personal.

Murray explained that the issue of a patient’s out-of-pocket costs connects with the drug’s list price when it comes to amount the patient has to pay when not subject to a standard co-payment for their Rx: that individual facing sticker shock may be one of four patient-payor personae: in the deductible phase if commercially insured; in the Medicare Part D donut hole; in catastrophic care; or, filling a prescription that carries coinsurance (a percent of the manufacturer’s list price).

That exposure has become much greater as more patients have enrolled in plans with high deductibles.

That’s why this has become a bigger issue, Murray explained.

We agreed — prescription drug pricing, from the patient’s point of view, is complicated, indeed.

But to that N of 1 patient, I said, it’s hugely personal. It impacts the household budget, already on average 20% of which is allocated to healthcare on a median national basis, HealthConsuming explains as the patient is the payor.

Yesterday’s Wall Street Journal featured an article on A $2 Million Therapy About to Hit [the] Market, discussing a new gene therapy treatment that addresses spinal muscular atrophy (SMA). Without a treatment, patients with this condition can die before their second birthday, which gives SMA the sobering distinction of being the most common genetic cause of infant death. This is a rare disease, with between 400 and 500 babies born with the genetic defect each year in the U.S.

“A therapy is useless if no one can afford it,” asserted Cathryn Donaldson from AHIP, the health insurance advocacy group, quoted in the story. AHIP has been a frequent critic of pharmaceutical and biotech industries in recent years as health reform targets have heated up in terms of regulation and price controls putting health insurance companies, pharma and biotech, and hospitals in the political bullseye on Capitol Hill, in State Houses, and as Aitken pointed out, “in the headlines.”

The politics of prescription drug pricing will continue to be personal for health care voters, I forecast in my own scenarios looking toward not 2023 — but 2020.

The post Prescription Drug Costs In America Through the Patient Lens, via IQVIA, GoodRx and a New $2 Million Therapy appeared first on HealthPopuli.com.

Prescription Drug Costs In America Through the Patient Lens, via IQVIA, GoodRx and a New $2 Million Therapy posted first on https://carilloncitydental.blogspot.com

0 notes

healthcaretrends-blog · 5 years

Text

Insulin Market Impressively growing Opportunities In 2026

The demand for insulin production is increasing to meet the treatment demand of the rising number of diabetic patients relying on insulin. This has led to increasing competition among market players to develop new insulin drugs in the market.

Insulin helps in promoting protein synthesis, glycogenesis, and glycolysis and in uptake of various ions. Earlier, insulin was isolated from sheep, and pigs, but later on, genetically modifying bacterial cells are also used to produce human insulin. Current treatment relies on developing commercial human insulin by recombinant DNA technology.

New product development and launches are expected to drive growth of global insulin market

Oramed Pharmaceuticals, in May 2018, developed the first oral drug delivery system, which stimulates the natural process of insulin in the liver. This insulin product is in phase II of clinical trial under the U.S. Food and Drug Administration (FDA) and this will provide efficient and safer method for delivering insulin therapy to patients.

Increasing investment on research, development, and manufacturing of anti-diabetic drugs is expected to boost global insulin market

Increasing research activities for the development of innovative diabetic management drugs by using technology such as delivering insulin without needle provides better opportunities for manufacturers in the global insulin market. For instance, from year 1952 to 2017, the American Diabetes Association (ADA) has invested US$ 807.4 million for over 4,700 research projects on diabetes.

In September 2017, Biocon Limited received funding from Juvenile Diabetes Research Foundation (JDRF) to study safety and efficacy of insulin Tregopil in diabetic patients. Insulin Tregopil is currently undergoing a pivotal Phase II/III study in type 2 diabetes patients in India. This fast acting insulin can improve post prandial glucose control with fewer side effects.

Get HOLISTIC Request Sample Copy Of This Business Report:

https://www.coherentmarketinsights.com/insight/request-sample/2183

Moreover, in September 2018, GeneSys Biologics Private Limited expanded research, development, and manufacturing unit in India for the development of insulin and its analogues biosimilars, allowing its research and development unit for commercial manufacturing.

Development of the insulin pens by various manufacturers is also expected to boost the global insulin market. For instance, in August 2018, Julphar Gulf Pharmaceutical Industries, one of the largest pharmaceutical company of the Middle East and Africa collaborated with Becton, Dickinson (BD) to sell disposable insulin pens in United Arab Emirates (UAE) region and are in final stage of approval and registration. Through this agreement, Julphar’s human insulin formulations Jusline R, Jusline N, and Jusline 30/70 will be available through BD’s portfolio of BD Vystra disposable pens.

However, increasing cost of insulin products especially drugs and stringent regulatory norms for approval of new drugs may hamper growth of the market. For instance, according to the Pharmaceutical Care Management Association (PCMA) report in May 2018, insulin price has increased by 10 folds in the past few years. According to PCMA, prices for Humulin/ Novolin have increased from US$ 25 per prescription in 1985 to around US$ 300 in 2016. Also, prices for long-acting insulins have increased from around US$ 100 per prescription in 2007 to around US$ 400 in 2016.Thus, increasing cost of such insulin therapies are restraining the global insulin market growth.

Global Insulin Market - Regional Analysis

On the basis of region, the global insulin market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold dominant position in terms of market share in the global insulin market, owing to increasing cases of diabetes, and geriatric population in this region. For instance, according to the Centers for Disease Control and Prevention report 2017, over 100 million adults are suffering with diabetes in the U.S in 2017. Asia Pacific region is expected to witness higher growth due to increasing awareness for diabetic care, favorable government policies, and increasing R&D investments by larger companies.

Global Insulin Market �� Competitive Landscape

Key players operating in the global insulin market include Eli Lilly and Company, Novo Nordisk A/ S, Julphar Gulf Pharmaceutical Industries, Sanofi S.A., Biocon Limited, GlaxoSmithKline, and Wockhardt. These companies are adopting strategies such as mergers, acquisitions, expansions, collaborations, and new product launches to retain their position in the global insulin market. For instance, in August 2018, Novo Nordisk acquired Ziylo to develop smart, glucose responsive insulin (GRIs), ensuring optimal glucose control and reducing risk of hypoglycemia.

Click To Reading More On Insulin Market

About Coherent Market Insights:

Also, Coherent Market Insights has a proprietary database of pipeline biologics and biosimilars, called PHASE-XS. This database provides analytical data in addition to the clinical information of ongoing trials for biologics and biosimilars. An amalgamation of more than 30 parameters, PHASE-XS helps biotechnology and pharmaceutical companies to analyze the market trend, competition, and market potential. For more information or to access this database, kindly click on the below link or contact at

[email protected]

https://www.coherentmarketinsights.com/phase-xs/

Mr.Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email:[email protected]

#Insulin Market

0 notes

expertofmarketinsights-blog · 6 years

Text

Insulin Market to Witness Widespread Expansion During 2026

Request for Sample Copy of Research Report: https://www.coherentmarketinsights.com/insight/request-sample/2183

New product development and launches are expected to drive growth of global insulin market

Global Insulin Market – Competitive Landscape

Else Put an Enquiry Before Purchasing Report : https://www.coherentmarketinsights.com/insight/talk-to-analyst/2183

Global Insulin Market – Taxonomy

The global insulin market is analyzed based on the following segmentations:

By Product Type

Drugs

Rapid Acting

Short Acting

Intermediate Acting

Long Acting

Premixed

Drug Delivery Devices

Pens

Syringes

By Distribution Channels

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By Region

North America

Latin America

Europe

Asia Pacific

Middle East

Africa

About Coherent Market Insights:

Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [email protected]

#Insulin Market #Insulin Market insights #Insulin Market growth #Insulin Market revenue #Insulin Market forecast

0 notes

market-research-future · 4 years

Text

Africa Medical Devices Market Profile, Opportunities, Global Industry Analysis By 2023

Africa Medical Devices Market Regional Analysis

Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/1813

Overview

Moreover, rising economic growth also drive the market in this region. According to the World Bank Group, in 2016, GDP of the Middle East & North Africa experienced the growth in GDP by 4.89%.

Competitive Analysis

Companies are continuously engaged in merger and acquisition activities for the development of the best medicine to cure affected population. Although the government stick rule hindering the growth of the market. In May 2017, Baxter International Inc. and Mayo Clinic announced a collaboration for the research and development to advance a spectrum of therapeutic areas to minimize the unmet patient needs. These collaborations help market players to lead the market of Africa. Most of the players from this region involve in the collaboration with global players to get advanced technology, which help them to maximize the market share in this region. Although limited infrastructure, lack of physicians, and restricted funding and reimbursement policy are the restraints factor for the growth of the market.

Browse Detailed Table of Content at: https://www.marketresearchfuture.com/reports/africa-medical-devices-market-2845

Brows More Healthcare Related Research Reports:

Infrared Spectroscopy Devices Market Size, Trends | Growth Analysis, 2023

Asia-Pacific Glaucoma Treatment Market Trends, Size Analysis | Applications, 2023

Diabetes Market Research Report Forecast To 2023 | MRFR

About Market Research Future:

Contact:

Akash Anand

Market Research Future

+1 646 845 9312

Email: [email protected]

0 notes

technicallyyoungkitten · 4 years

Text

Wearable Patch Market -Size, Share, Outlook, and Opportunity Analysis, 2020- 2027

The global wearable patch market size is expected to be valued at US$ 318.1 million in 2019, and is expected to exhibit a CAGR of 22.9% over the forecast period (2019-2027).

Browse Summary of the Research Report-https://www.coherentmarketinsights.com/market-insight/wearable-patch-market-2891

Rising technological advancements in wearable patch is anticipated to drive the market growth over the forecast period

Key Players

Request A Sample Copy -https://www.coherentmarketinsights.com/insight/request-sample/2891

About Coherent Market Insights: Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [email protected] ******************************************************************************************************************

0 notes

smitadeshmukh123 · 7 years

Text

Pain Management Therapeutics Market: Rising Geriatric Population and Favorable Regulatory Scenario to Boost Consumption of Pain Management Drugs

With generic medicines accounting for a more than two-thirds of the global pain management therapeutics market, several small- and medium-scale generic drug manufacturers will venture in the market and make it highly saturated in the near future, states TMR in a recent report. The segment of branded pain management therapeutics features the presence of some of the leading international pharmaceutical giants, including Merck & Co, Inc. Pfizer,Inc., Endo Health Solutions, Johnson & Johnson, and Purdue Pharma LP.

In the branded drugs segment, the top two companies, Pfizer,Inc. and Purdue Pharma LP, accounted for over 50% share in 2015. Over the forecast period, the overall share of the branded drugs manufacturers in the global pain management therapeutics market will further decline. “Major vendors will lose market share to emerging vendors such as Depomed, Inc. and AstraZeneca plc. and the competition in the generic drugs segment will further intensify,” quotes a TMR analyst.

This 130 page report gives readers a comprehensive overview of the pain management therapeutics market. Browse through 13 data tables and 64 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/pain-management-therapeutics.html

Alarming Rise in Prevalence of Chronic Diseases Emerges as High-impact Driver

The number of patients suffering from chronic pain is rising at a substantial pace globally. According to the WHO, nearly 116 mn people were suffering from chronic pain in 2011 in the U.S. alone. According to another survey, one in five people in Europe suffer from chronic pain every year.

The rising prevalence of chronic diseases such as a variety of cancers and diabetes further contribute to the further contributes to the number of people suffering from chronic pain, encouraging the use of pain management drugs. Medications for alleviating the pain occurring from cancer therapy and from the intrusion of cancer cells in bones and other body parts, for instance, accounted for over 28% share of the overall pain management therapeutics market’s overall valuation in 2015.

Rising Geriatric Population and Favorable Regulatory Scenario to Boost Consumption of Pain Management Drugs

The vast rise in the world’s geriatric population is also expected to emerge as a key growth driver for the global pain management therapeutics market from 2106 to 2024. Aged people are more prone to diseases such as arthritis, joint or bone pain, epilepsy, depression, nerve damage, diabetic neuropathy, and a variety of injuries owing to low immunity levels or gene alteration. The global population of geriatrics (people aged more than 65 years) is expected to rise to 2 bn by 2050, accounting for nearly 22% of the projected global population by then. This demographic will lead to a substantial rise in the overall global demand for numerous pain management drugs, thereby driving the global pain management therapeutics market.

Additionally, favorable regulations are playing a key role in the increased rate of development, approval, and commercialization of novel molecule combinations and drug delivery techniques in the pain management therapeutics sector. The instigation of a large number of regulatory healthcare reforms, favoring development of methods for the improved diagnosis and treatment of chronic pain, will help the pain management therapeutics tread along a promising growth path in the next few years.

Patent Expiries of Blockbuster Drugs and Rising Uptake of Generics Could Pose Existential Threat to Established Players

Request a sample of this report to know what opportunities will emerge in the rapidly evolving pain management therapeutics market during 2016 - 2024: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1059

Impending patent expiries of several blockbuster pain management drugs in the global market is one of the key high-impact challenges for the global pain management therapeutics market presently. Cheaper generic versions of once high-earning drugs will deal a huge blow to the overall revenues of several established vendors in the global pain management therapeutics market in the next few years.

The factor will also cause a substantial decline in the overall revenues of the global market. Moreover, the rapid influx of several new vendors with generic versions of once groundbreaking medications will lead to intense competition in the market for generic drugs for pain management therapeutics.

In terms of product types, the global pain management therapeutics market is presently dominated by opioids and Non-steroidal Anti-inflammatory Drugs (NSAIDS), which collectively accounted for over 52% of the market’s overall revenues in 2015. North America dominated the market, accounting for over 56% of the overall market in the same year.

On a whole, the global pain management therapeutics market is expected to expand at a 3.7% CAGR over the period between 2016 and 2024. At this pace, the market is expected to rise from a valuation of US$60.2 bn in 2015 to US$83.0 bn by 2024.

This review of the global pain management market is based on a recent market research report, titled “Pain Management Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2016-2023.”

#Pain Management Therapeutics Market

0 notes

pharmanewstrands-blog · 5 years

Text

Insulin Market - Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026

New product development and launches are expected to drive growth of global insulin market

Furthermore, in February 2018, Sanofi Aventis launched Toujea in India, a next generation basal insulin, with once or daily usage forms which improves glycemic control in adults with type 1 and type 2 diabetes. Increasing investment on research, development, and manufacturing of anti-diabetic drugs is expected to boost global insulin market

Request A Sample Copy:

https://www.coherentmarketinsights.com/insight/request-sample/2183

Global Insulin Market - Regional Analysis

Global Insulin Market – Competitive Landscape

Global Insulin Market – Taxonomy

The global insulin market is analyzed based on the following segmentations:

By Product Type

Drugs,Rapid Acting,Humalog,Novolog,Apidra,Short Acting,Novolin R

Humulin R,Intermediate Acting,Humulin N,Novolin NLong Acting

Levemir,Degludec,antus,Basaglar,Premixed,Humalog

Mix,Novolog Mix,Drug Delivery Devices,Pens,Syringes

By Distribution Channels

Hospital Pharmacies,Retail Pharmacies,Online Pharmacies

By Region

North America,Latin America,Europe,Asia Pacific,Middle East,Africa

Click To Read More On Insulin Market

About Coherent Market Insights:

Mr.Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email:[email protected]

#insulin market insulin market trends insulin market growth

0 notes